Literature DB >> 10920136

First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma.

M N Beck1, A Balmer, C Dessing, A Pica, F Munier.   

Abstract

PURPOSE: To evaluate the efficacy of first-line chemotherapy (CT) in preventing external-beam radiotherapy (EBR) and/or enucleation in patients with retinoblastoma (Rbl). PATIENTS AND METHODS: Twenty-four patients with newly diagnosed unilateral or bilateral Rbl received CT associated with local treatment (LT). Two to five courses of etoposide and carboplatin were administered at 3- to 4-week intervals, depending on tumor response, and were completed each time by LT.
RESULTS: Tumor response was observed in all eyes. Twenty-one of 24 patients showed a complete response (CR) that persisted at a median follow-up (FU) of 31 months (range, 4 to 41 months). Among the three patients who relapsed, two were lost to FU and one died of progressive disease. CR was achieved by CT and LT alone in 15 (71.4%) of 21 patients with less advanced disease (groups I to III). Six other patients with advanced disease (groups IV and V) experienced treatment failure and needed salvage treatment by EBR and/or enucleation. The difference between the two patient groups with regard to disease stage was statistically significant (P <.0001). EBR could be avoided in 13 (68.4%) of 19 patients, who presented with groups I to III (15 eyes) and group V (one eye) disease, whereas enucleation could be avoided in only two (40%) of five.
CONCLUSION: CT combined with intensive LT is effective in patients with groups I to III Rbl, permitting the avoidance of EBR in the majority of these young children and, thus, reducing the risk of long-term sequelae. This is in contrast with the disappointing results for patients with groups IV and V Rbl, in whom EBR and/or enucleation was needed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920136     DOI: 10.1200/JCO.2000.18.15.2881

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Radiotherapy in ophthalmology : 2004 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Leonidas Zografos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07       Impact factor: 3.117

2.  In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.

Authors:  Sai H S Boddu; Jwala Jwala; Monica R Chowdhury; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

3.  Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age.

Authors:  Dan S Gombos; Alison Kelly; Pietro G Coen; Judith E Kingston; John L Hungerford
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

4.  Systemic carboplatin for retinoblastoma: change in tumour size over time.

Authors:  D H Abramson; S D Lawrence; K L Beaverson; T C Lee; I S Rollins; I J Dunkel
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

5.  Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Authors:  Steven Allen; Matthew W Wilson; Amy Watkins; Catherine Billups; Ibrahim Qaddoumi; Barrett H Haik; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

6.  Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study.

Authors:  P-R Rothschild; D Lévy; A Savignoni; L Lumbroso-Le Rouic; I Aerts; M Gauthier-Villars; M Esteve; D Bours; L Desjardins; F Doz; C Lévy-Gabriel
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

7.  Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.

Authors:  Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows
Journal:  Pediatr Blood Cancer       Date:  2016-12-26       Impact factor: 3.167

8.  Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy.

Authors:  L Lumbroso-Le Rouic; I Aerts; D Hajage; C Lévy-Gabriel; A Savignoni; N Algret; N Cassoux; A-I Bertozzi; M Esteve; F Doz; L Desjardins
Journal:  Eye (Lond)       Date:  2015-10-02       Impact factor: 3.775

Review 9.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.